FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense for Early-Stage Breast Cancer

IceCure Medical Ltd. has announced that the Food and Drug Administration (FDA) has granted its appeal and reopened its De Novo Classification Request for Marketing Authorization of its ProSense cryoablation technology for early-stage breast cancer.

Related Keywords

California ,United States ,Tennessee ,Centrastate Medical Center ,New Jersey ,Germantown ,Long Beach ,Princeton ,American ,Kenneth Tomkovich ,Eyal Shamir ,Penn Princeton Medical Center ,Ontario Clinical Oncology Group Canada ,Drug Administration ,Society Of Interventional Oncologysio Annual Scientific Meeting ,American Society Of Breast Surgeons ,Breast Center ,Icecure Medical Ltd ,Icecure Medical ,Prosense System ,Ice Cure ,Ontario Clinical Oncology Group ,Cure Participates ,Cryoablation Master ,Scientific Meeting ,Cryoablation Master Class ,Principal Investigator ,Interventional Radiologist ,Princeton Radiology ,Richard Fine ,American Society ,Breast Surgeons ,Program Director ,Breast Surgical Oncology Fellowship ,West Comprehensive Breast Center ,Master Class ,